iX Biopharma Ltd: iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

iX Biopharma will receive an initial US$9 million upfront payment Eligible for up to US$239 million in development and sales milestone payments Double digit royalties on future product

Related Keywords

United States ,New York ,Australia ,Taiwan ,Hong Kong ,Singapore ,China ,Macau ,Raj Mehra ,Kostenloser Wertpapierhandel ,Yee Chia Hsing ,Geddy Lee ,X Biopharma Waferi ,Seelos Therapeutics Inc ,Drug Administration ,Nasdaq ,European Medicines Agency ,Singapore Exchange Securities Trading Limited ,Ix Biopharma Ltd ,Corporate Affairs ,Seelos Therapeutics Inc Nasdaq ,Seelos Therapeutics ,Scientific Advice ,Complex Regional Pain Syndrome ,Licensed Products ,Biopharma ,Signs ,Exclusive ,License ,Agreement ,Afermine ,Mother ,Sublingual ,Ketamine ,Wafer ,Products ,